Late-Breaking Data on Bladder Cancer Treatments...

By HEOR Staff Writer

February 13, 2026

Breakthroughs in Bladder Cancer Treatments at ASCO GU Merck unveiled promising bladder cancer treatments at the 2026 ASCO Genitourinary (GU) Cancers Symposium, showcasing data fr...
AstraZeneca Financial Results: Strong Revenue Growth and Pipeline Expansion i...
KEYTRUDA Ovarian Cancer Treatments: FDA Approves New Regimens for Platinum-Re...
National HealthTech Access: Transforming NHS Adoption and Equity
Datroway Metastatic Breast Cancer: FDA Grants Priority Review for Breakthroug...
FDA Confirms GLP-1 RA Safety Review: No Increased Suicidal Risk
CHMP January 2026 Approvals: Expanding Access to Innovative Therapies
Accelerating FAST-EU Clinical Trials
Alzheimer’s Care Innovation: Advancing Implementation Across Europe
β-Blockers Myocardial Infarction: Reevaluating Their Role in Patients with Pr...
Epidyolex Spending in Portugal Exceeds €3 Million Amid Regulatory Delays
Johnson & Johnson’s EMA Application for Teclistamab Daratumumab Th...
mRNA Vaccine Advancements: Transforming Infectious Disease Prevention and Equity